NYC startupfromMedCity News2 months agoBioNTech to Buy CureVac in $1.25B Stock Deal That Would Also End mRNA Patent Dispute - MedCity NewsBioNTech acquires CureVac to strengthen mRNA capabilities and mitigate legal risks amidst ongoing patent disputes.
London startupfromwww.independent.co.uk3 months agoVaccine maker's 1bn UK investment to create hundreds of high-skilled jobs'BioNTech's investment will significantly enhance the UK's life sciences sector by creating jobs and fostering research.